FRANCISCO JAVIER
SALMERÓN ESCOBAR
Investigador en el periodo 2002-2020
Hospital Universitario de Valme
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Valme (29)
2021
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
2020
-
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Antiviral Research, Vol. 174
2019
-
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort
Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 55-64
-
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world
Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888
-
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort
PLoS ONE, Vol. 14, Núm. 8
2018
-
Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C
Journal of Hepatology, Vol. 68, Núm. 5, pp. 940-948
-
Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis
PLoS ONE, Vol. 13, Núm. 7
2017
-
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry
Hepatology, Vol. 65, Núm. 6, pp. 1810-1822
2016
2015
-
Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis
World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174
-
Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection
Genes and Immunity, Vol. 16, Núm. 5, pp. 297-300
-
High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods
Journal of Clinical Microbiology, Vol. 53, Núm. 1, pp. 219-226
2011
-
Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin
American Journal of Gastroenterology, Vol. 106, Núm. 7, pp. 1246-1254
-
La respuesta virológica al tratamiento con adefovir dipivoxil predice el desarrollo de resistencias a largo plazo en pacientes con hepatitis crónica B HBeAg negativo previamente no tratados
Gastroenterologia y Hepatologia, Vol. 34, Núm. 2, pp. 69-74
2009
-
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin
Hepatology, Vol. 50, Núm. 6, pp. 1702-1708
2008
-
Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C
Journal of Hepatology, Vol. 48, Núm. 5, pp. 721-727
-
Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C
Hepatology, Vol. 47, Núm. 3, pp. 810-816
-
Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin
Journal of Clinical Virology, Vol. 41, Núm. 4, pp. 264-269
2007
-
Induction doses of interferon-α-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: A randomized trial
Journal of Viral Hepatitis, Vol. 14, Núm. 2, pp. 89-95
-
Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate
Alimentary Pharmacology and Therapeutics, Vol. 25, Núm. 8, pp. 899-906